Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer

October 16th 2023

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Best Practices for Patient Education Surrounding Cancer Treatment

October 13th 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Molecular Testing Considerations in Cancer Treatment

October 13th 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

October 13th 2023

Jane Meisel, MD, details the current standard-of-care for HER2+ metastatic breast cancer in the US, emphasizing personalized care and the importance of shared decision-making with patients.

Evolution of Advanced HER2+ Breast Cancer Management

October 13th 2023

Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.

Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer

October 12th 2023

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Dr Vikas on the Benefit of Utilizing MRD Detection in Breast Cancer Treatment

October 12th 2023

Praveen Vikas, MBBS, discusses the benefits associated with utilizing minimal residual disease detection in breast cancer.

Let’s Talk About Post-Mastectomy Chest Numbness

October 11th 2023

Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.

Advice For Providers Caring for Patients With HR+/HER2- mBC

October 10th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.

Remaining Unmet Needs for Patients With HR+/HER2- mBC

October 10th 2023

Experts highlight some remaining unmet needs in the treatment and management of patients with HR+/HER2- metastatic breast cancer.

Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis

October 9th 2023

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

Dr Haffty on the Rationale for Investigating Preoperative Radiation Boosts in Breast Cancer

October 7th 2023

Bruce Haffty, MD, MS, discusses the rationale for launching a clinical trial to assess the feasibility of preoperative radiation boost in patients with breast cancer.

Biomarker Testing in Gastrointestinal and Lung Cancers

October 6th 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

Molecular Testing in Breast Cancer

October 6th 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

Dr Haffty on the Feasibility of Preoperative Radiation Boost in Breast Cancer

October 5th 2023

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

SABR to Oligoprogressive Lesions Delays Systemic Therapy Change in ER+ Advanced Breast Cancer

October 5th 2023

Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.

Reduced-Dose and Partial-Breast Radiotherapy Sustain Long-Term Safety and Efficacy in Early-Stage Breast Cancer

October 4th 2023

Treatment with reduced-dose or partial-breast radiotherapy sustained long-term safety and elicited similar rates of ipsilateral breast tumor relapse compared with whole-breast radiotherapy in patients with early-stage breast cancer.

Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer

October 4th 2023

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Preoperative S-PBI Plus Endocrine Therapy is Safe, Produces Responses in Early-Stage ER+ Breast Cancer

October 4th 2023

Ablative preoperative stereotactic partial breast irradiation plus endocrine therapy was safe at a single fraction of 34 Gy and generated pathological complete responses and near complete responses in patients with early-stage, estrogen receptor-positive breast cancer.

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC

October 3rd 2023

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.